Leonor Fernandes

Dr. Leonor Fernandes

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in CNS Oncology
Verified
Journal Article
Open access
LFLeonor Fernandes
Leonor Fernandes
Leonor Vasconcelos de MatosLeonor Vasconcelos de Matos
Leonor Vasconcelos de Matos
DCDébora Cardoso
Débora Cardoso
MSMarlene Saraiva
Marlene Saraiva
RMRenata Medeiros-Mirra
Renata Medeiros-Mirra
AMAna Martins
Ana Martins
Leptomeningeal disease (LMD) represents a devastating complication of advanced breast cancer (ABC), with survival of <5 months with multimodal treatment. The role of endocrine therapy (ET), due to ...

10 January 2022 in Archive of Clinical Cases
Verified
Journal Article
Open access
PDF file
MBMafalda Miranda Baleiras
Mafalda Miranda Baleiras
JGJoana Graça
Joana Graça
LFLeonor Fernandes
Leonor Fernandes
MCMartinha Chorao
Martinha Chorao
AVAna Carolina Vasques
Ana Carolina Vasques
MPMarta Mesquita Pinto
Marta Mesquita Pinto
Leptomeningeal carcinomatosis (LMC) is exceedingly rare in gastric cancer. It is most commonly seen in breast, lung cancer and melanoma, and is associated with an extremely poor prognosis. If untreated, median overall survival is four to six weeks. No standard treatment for LMC exists and published data are scarce. We present two cases of gastric carcinoma diagnosed with LMC that exemplify how aggressive this condition is and how short the time lapse is to perform any targeted therapy. This report aims to raise awareness of this rare metastatic possibility in gastric cancer and its diagnostic and therapeutic challenges.

23 September 2020 in Dermatology Reports
Verified
Journal Article
Open access
PDF file
LFLeonor Fernandes
Leonor Fernandes
JGJoana Graça
Joana Graça
Leonor Vasconcelos de MatosLeonor Vasconcelos de Matos
Leonor Vasconcelos de Matos
RSRita Sampaio
Rita Sampaio
MBMafalda Miranda Baleiras
Mafalda Miranda Baleiras
AMAna Martins
Ana Martins
Extramammary Paget Disease (EMPD) is an often-misdiagnosed rare disorder, whose cause remains unknown. Diagnosis is confirmed by skin biopsy. Primary treatment for EMPD is surgery. Recurrence is common in the first two years and prognosis is good if the disease is localized and there is no underlying associated cancer. Patients with invasive and metastatic EMPD are uncommon and exhibit a poor prognosis, even when there is good response to a first chemotherapy line. Multiple chemotherapeutic regimens, with varying levels of success, have been attempted, but standard of care is not established. The central nervous system seems to be a common metastatic site with better survival than visceral metastasis.We report a case of metastatic EMPD that addresses the difficulties associated with the treatment of this rare disease, that has no current guidelines.

26 February 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
Leonor Vasconcelos de MatosLeonor Vasconcelos de Matos
Leonor Vasconcelos de Matos
LFLeonor Fernandes
Leonor Fernandes
MNMaria Teresa Neves
Maria Teresa Neves
FAFátima Alves
Fátima Alves
MBMafalda Baleiras
Mafalda Baleiras
AMAna Martins
Ana Martins
Aromatase inhibitors (AI) are extensively used as adjuvant endocrine therapy in post-menopausal women with hormone receptor-positive early breast cancer (HR+ EBC), but their impact on bone health is not negligible. This work aimed to assess bone loss, fracture incidence, and risk factors associated with these events, as well as the prognostic influence of fractures. We have conducted a retrospective cohort study of women with HR+ EBC under adjuvant therapy with AI, during a 3-year period. Four-hundred-and-fifty-one eligible women were reviewed (median age 68 years). Median time under AI was 40 months. A fracture event occurred in 8.4%, mostly in the radium and femoral neck and in older women (mean 74 vs. 68 years, p = 0.006). Age (OR 1.01, 95% CI 1.01–1.07, p = 0.024) and time under AI (OR 1.02, 95% CI 1.00–1.04, p = 0.037) were independent predictors of fracture, with a fair discrimination (AUC 0.71). Analysis of disease-free survival according to fracture event varied between groups, disfavoring the fracture cohort (at 73 months, survival 78.6%, 95% CI, 47.6–92.4 vs. 95.6%, 95% CI, 91.2–97.8, p = 0.027). The multivariate model confirmed the prognostic impact of fracture occurrence (adjusted HR of 3.17, 95% CI 1.10–9.11; p = 0.032). Bone health is often forgotten, despite its great impact in survivorship. Our results validate the pathophysiologic link between EBC and bone metabolism, which translates into EBC recurrence. Further research in this area may help refine these findings. Moreover, early identification of women at higher risk for fractures is warranted.

1 January 2019 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
DCDebora Cardoso
Debora Cardoso
ACAndreia Coelho
Andreia Coelho
LFLeonor Fernandes
Leonor Fernandes
Leonor Vasconcelos de MatosLeonor Vasconcelos de Matos
Leonor Vasconcelos de Matos
ISIsabel Serrano
Isabel Serrano
AMAna Martins
Ana Martins
Background: Breast cancer is the most commonly diagnosed cancer in women, mainly at an early stage, allowing treatment with curative intent. Aromatase inhibitors are widely used in the adjuvant treatment of oestrogen receptor-positive breast cancer, mainly in postmenopausal women. The most frequent adverse events associated with these therapies are musculoskeletal symptoms and an increased risk of bone fractures. Cutaneous adverse events have been rarely described. Sweet’s syndrome can present as an idiopathic disorder in addition to being malignancy-associated or drug-induced. Case presentation: We report the case of a 69-year old woman, diagnosed with early stage breast cancer, who underwent breast-conserving surgery, followed by adjuvant radio and endocrine treatment with letrozole 2.5 mg daily, for a foreseeable duration of 5 years. Three months after starting letrozole, she presented with sudden fever and exuberant and painful erythematous skin papules and plaques on her upper body. After a full work-up and exclusion of other potential causes, a skin biopsy confirmed the presence of dermal oedema and a diffuse neutrophilic infiltrate, suggesting Sweet’s syndrome. After discontinuation of letrozole and treatment with corticosteroids, the patient fully recovered. She resumed adjuvant treatment with tamoxifen, without symptom recurrence. Conclusions: Sweet’s syndrome is a rare condition and an association with aromatase inhibitors has not been previously reported. Although its occurrence has already been observed in the onset of malignancies such as breast cancer, aromatase inhibitors must be added to the list of potential causes of drug-induced Sweet’s syndrome.

13 March 2025 in European Journal of Breast Health
Verified
Journal Article
Open access
MMMaria Alexandra Montenegro
Maria Alexandra Montenegro
TDTiago Dias Domingues
Tiago Dias Domingues
TGTeresa Mota Garcia
Teresa Mota Garcia
RFRita Quaresma Ferreira
Rita Quaresma Ferreira
IFIvánia Tavares Furtado
Ivánia Tavares Furtado
SOSónia Duarte Oliveira
Sónia Duarte Oliveira
Male Breast Cancer in Portugal: A Descriptive Analysis of a 20-Year Cohort - European Journal of Breast Health